For the Inventor, By the Inventor

Enter assignee name

Pasadena, CA, United States of America

Arrowhead Pharmaceuticals, Inc.

USPTO Granted Patents = 102

% Expired Patents = 3.9

EPO Patents = 23

Trademarks = 2

Forward Citations = 160

Loading Chart...

Loading Chart...

135 inventors (with patents filed for the assignee):

Tao Pei (34 out of 35 patents)

Zhen Li (29 out of 35 patents)

Darren H Wakefield (26 out of 58 patents)

4. David B Rozema (22 out of 83 patents)

5. David L Lewis (19 out of 44 patents)

6. Lauren Almeida (18 out of 20 patents)

7. Rui Zhu (17 out of 20 patents)

8. Anthony Nicholas (17 out of 19 patents)

9. Jeffrey Carlson (15 out of 21 patents)

10. Steven B Kanner (14 out of 40 patents)

11. Stuart Milstein (12 out of 94 patents)

12. Christine I Wooddell (12 out of 15 patents)

13. Jon E Chatterton (12 out of 47 patents)

14. So Wong (11 out of 19 patents)

15. Aaron Almeida (10 out of 10 patents)

Core Competencies:

RNAi Agents

Hepatitis B Virus

Apolipoprotein C-III

Alpha-1 Antitrypsin

Gene Expression Inhibition

Therapeutic Compounds

Targeting Ligands

Compositions

Microtubule Associated Protein Tau

Integrin Ligands

Nucleotides

Organic Compositions

102 patents: Sort by Forward Citations

1. 12729377 - RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use (2026-09-08),

2. 12667619 - INTEGRIN TARGETING LIGANDS AND USES THEREOF (2026-06-30),

3. 12655428 - RNAi Agents for Inhibiting Expression of Beta-ENaC, Compositions Thereof, and Methods of Use (2026-06-16),

4. 12630826 - RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use (2026-05-19),

5. 12551569 - RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use (2026-02-17),

6. 12527877 - ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOF (2026-01-20),

7. 12503696 - RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions thereof, and methods of use (2025-12-23),

8. 12442002 - RNAi agents for inhibiting expression of activin receptor-like kinase 7 (ALK7), compositions thereof, and methods of use (2025-10-14),

9. 12441756 - 5'-cyclo-phosphonate modified nucleotides (2025-10-14),

10. 12378558 - RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use (2025-08-05),

11. 12365899 - RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) (2025-07-22),

12. 12365897 - RNAi agents for inhibiting expression of mucin 5AC (MUC5AC), compositions thereof, and methods of use (2025-07-22),

13. 12221610 - RNAi agents for inhibiting expression of HIF-2 alpha (), compositions thereof, and methods of use (2025-02-11),

14. 12188017 - Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin (2025-01-07),

15. 12173086 - Alpha-v beta-6 integrin ligands and uses thereof (2024-12-24),

Company Overview

Arrowhead Pharmaceuticals, Inc., based in Pasadena, California, specializes in the development of innovative therapeutics utilizing RNA interference (RNAi) technology. The company focuses on creating RNAi agents aimed at treating various diseases, including those associated with the hepatitis B virus and conditions linked to apolipoprotein C-III and alpha-1 antitrypsin. Arrowhead's research emphasizes gene expression inhibition and the design of therapeutic compounds with specific targeting ligands, contributing to advancements in precision medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

102 Patents

#4 in Pasadena, CA

#851 in California

#3,725 in US

#7,654 in the World

Pasadena, CA, United States of America

Arrowhead Pharmaceuticals, Inc.

Forward Citations = 160

135 inventors:

Tao Pei (34 out of 35 patents)

Zhen Li (29 out of 35 patents)

Darren H Wakefield (26 out of 58 patents)

4. David B Rozema (22 out of 83 patents)

5. David L Lewis (19 out of 44 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Arrowhead Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/arrowhead-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…